Biocon & Mylan launch the Semglee (insulin glargine solution for injection 100 IU/mL in a 3mL pre-filled pen) as the first Insulin Glargine biosimilar in Australia available on the PBSThe TGA approval is based on the data demonstrated high bio-similarity of Semglee with the reference- Insulin Glargine. The launch of Semglee will increase patients access to the therapy and reduces the cost burden for PBSInsulin glargine (qd) is a long-acting basal insulin analog- helps to control the blood sugar levels in diabetes and is one of the three insulin analogs being co-developed by Mylan and Biocon. Mylan holds exclusive commercialization rights of Semglee in the US- Canada- Australia- New Zealand & EU while Biocon grasps exclusive commercialization rights in Japan & few emerging markets with co-exclusive commercialization rights with Mylan in ROW
Click here to read full press release/ article | Ref: Biocon | Image: Pinterest
